Industry watchers have been speculating for months about just how high Novartis would price gene therapy Zolgensma—and just how payers would cover the “transformative” spinal muscular atrophy treatment. Now, they have their answers. More: Novartis slaps M-plus price tag on
read moreSince its inception in 1948, the World Health Organization’s role has been, in part, to provide international prescribing guidance without an eye on profits. But what happens when a fox is let loose in the henhouse, and that guidance is
read moreAfter 19 salespeople resigned from Amgen last year to join Karyopharm, which is preparing to launch a rival multiple myeloma drug, Amgen sued, alleging theft of trade secrets. Now, as it awaits an FDA decision on its multiple myeloma drug
read moreThink disclosing drug list prices in TV ads is all the transparency the Trump administration is asking for? Think again. The president is reportedly going to sign an executive order that would require disclosure of prices across the healthcare industry,
read moreThe drug should be available for routine use within 90 days for patients in England. More: Final NICE guidance issued for Akcea’s Tegsedi Source: News
read moreThe company implemented stricter rules in 2012 as part of a broad transparency initiative. More: GSK updates its sales rep incentives Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals